Prospective Study
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Apr 15, 2025; 17(4): 103029
Published online Apr 15, 2025. doi: 10.4251/wjgo.v17.i4.103029
Phase angle as a prognostic biomarker in metastatic colorectal cancer: A prospective trial
Domina Kekez, Juraj Prejac, Gordan Adžić, Nikša Librenjak, Irma Goršić, Danijela Jonjić, Željko Krznarić, Goran Augustin, Stjepko Pleština
Domina Kekez, Juraj Prejac, Gordan Adžić, Nikša Librenjak, Irma Goršić, Danijela Jonjić, Stjepko Pleština, Department of Oncology, University Hospital Centre Zagreb, Zagreb 10000, Grad Zagreb, Croatia
Domina Kekez, Juraj Prejac, School of Dental Medicine, University of Zagreb, Zagreb 10000, Grad Zagreb, Croatia
Željko Krznarić, Department of Internal Medicine, University Hospital Centre Zagreb, Zagreb 10000, Grad Zagreb, Croatia
Željko Krznarić, Stjepko Pleština, School of Medicine, University of Zagreb, Zagreb 10000, Grad Zagreb, Croatia
Goran Augustin, Department of Surgery, University Hospital Centre Zagreb, Zagreb 10000, Grad Zagreb, Croatia
Author contributions: Kekez D and Prejac J designed the study; Kekez D, Librenjak N, Goršić I, and Jonjić D participated in collecting data and drafting the manuscript; Adžić G and Prejac J did a statistical analysis and revised the manuscript; Pleština S helped design the study and revised the manuscript; Krznarić Ž and Augustin G revised the manuscript.
Institutional review board statement: The study was approved by the Ethical Committee of the University Hospital Centre Zagreb (No. 8.1-21/1281-2) and conducted under the guidelines of the Declaration of Helsinki.
Clinical trial registration statement: Given that this is a prospective study and no experimental drug was investigated, registration on ClinicalTrials.gov is not required.
Informed consent statement: Written informed consent was obtained from the patients for data collection.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
CONSORT 2010 statement: The authors have read the CONSORT 2010 Statement, and the manuscript was prepared and revised according to the CONSORT 2010 Statement.
Data sharing statement: The raw data supporting the conclusions of this article will be made available by the authors without undue reservation by corresponding author at juraj.prejac@gmail.com.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Juraj Prejac, MD, PhD, Department of Oncology, University Hospital Centre Zagreb, Kišpatićeva 12, Zagreb 10000, Grad Zagreb, Croatia. jprejac@kbc-zagreb.hr
Received: November 6, 2024
Revised: December 29, 2024
Accepted: January 20, 2025
Published online: April 15, 2025
Processing time: 140 Days and 4.5 Hours
Core Tip

Core Tip: Most patients with metastatic colorectal cancer (mCRC) experience malnutrition during their illness, resulting from both the disease and the treatment. Assessing the nutritional status of these patients is crucial due to its negative impact on treatment outcomes. Our objective was to establish the phase angle (PA) as a prognostic indicator for survival in mCRC patients. Our findings indicate that patients with a high PA (≥ 4.60°) have a considerably longer median progression-free survival during first-line treatment. PA, assessed using a bioelectrical impedance analysis scale, is a non-invasive and easily obtainable measure that can serve as an independent prognostic factor for survival in managing mCRC.